Peter Slasor

4.1k citations

29 papers · 3.1k indexed · 3 hit papers · h-index 14

Pathology and Forensic Medicine top 1%
Rheumatology top 1%
- Glycogen Storage Diseases and Myoclonus 14
Neurology top 2%
Physiology top 2%
- Lysosomal Storage Disorders Research 20
- Calcium signaling and nucleotide metabolism 2
Psychiatry and Mental health top 5%
Epidemiology
- Trypanosoma species research and implications 8
Molecular Biology
- Biochemical and Molecular Research 4
Cell Biology
- Cellular transport and secretion 4
Statistics and Probability
- Statistical Methods and Bayesian Inference 2
- Statistical Methods and Inference 2

Co-authors: Nan M. Laird Avital Cnaan Lawrence Jacobs R. Phillip Kinkel T. J. Murray Alfred Sandrock Nancy A. Simonian Carol M. Brownscheidle
Cited by: Pathology and Forensic Medicine Rheumatology Neurology
Journals: Molecular Genetics and Metabolism (9 papers)New England Journal of Medicine (2 papers)Statistics in Medicine (2 papers)
Partner nations: United States Germany Italy

In The Last Decade

Peter Slasor

29 papers receiving 3.0k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2018 New England Journal of Medicine
2000 New England Journal of Medicine
1997 Statistics in Medicine

Peers

Countries citing papers authored by Peter Slasor

Since Specialization

Citations

This map shows the geographic impact of Peter Slasor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Slasor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Slasor more than expected).

Fields of papers citing papers by Peter Slasor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Slasor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Slasor. The network helps show where Peter Slasor may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Peter Slasor, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Slasor Line = papers co-authored together Peter Slasor links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Real-world clinical outcomes of patients with CLN2 disease treated with cerliponase alfa Frontiers in Neurology ·Angela Schulz,Yusufjon Mizomov,Protik Mazumder,Paulo F Nogueira,Mengyuan T. Liu,Susanne Lezius,Ashok Kumar Jha,Masco Tokuda,Peter Slasor,克尚臼井,Miriam Nickel	2025	1
2	Exploring concurrent validity of the CLN2 Clinical Rating Scale: Comparison to PedsQL using cerliponase alfa clinical trial data PLoS ONE ·Nicola Specchio,Paul Gissen,Emily de los Reyes,Andrew Olaye,Charlotte Camp,金延萍,P. Thieberger,Thomas Butt,Jessica Cohen‐Pfeffer,Peter Slasor,Zlatko Sisic,Mohit Jain,Angela Schulz	2024	2
3	Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study The Lancet Neurology ·Angela Schulz,Nicola Specchio,Emily de los Reyes,Paul Gissen,Miriam Nickel,Marina Trivisano,Shawn C. Aylward,Anupam Chakrapani,Yusufjon Mizomov,Protik Mazumder,Paulo F Nogueira,Douglas Ballon,Jonathan P. Dyke,Anu Cherukuri,Shinya Hibino,Peter Slasor,Ann Lukasevich	2023	15
4	Cerliponase alfa for the treatment of CLN2 disease in an expanded patient cohort including children younger than three years: Interim results from an ongoing clinical study Molecular Genetics and Metabolism ·Angela Schulz,Emily de los Reyes,Nicola Specchio,Paul Gissen,Heather Cahan,Peter Slasor,Temitayo Ajayi	2020	1
5	Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration Clinical and Translational Science ·Aryun Kim,Anita Grover,Stuart Formby,Nong Pi-zhong,Peter Slasor,Anu Cherukuri,Temitayo Ajayi,David Jacoby,Angela Schulz,Nicola Specchio,Emily de los Reyes,Paul Gissen,Joshua W. Henshaw	2020	7
6	Persistent Treatment Effect of Cerliponase Alfa in Children with CLN2 Disease: A 3 Year Update from an Ongoing Multicenter Extension Study Neuropediatrics ·Angela Schulz,Nicola Specchio,Paul Gissen,Emily de los Reyes,Heather Cahan,Peter Slasor,David Jacoby,Temitayo Ajayi	2019	6
7	Persistent treatment effect of cerliponase alfa in children with CLN2 disease: A 3 year update from an ongoing multicenter extension study Molecular Genetics and Metabolism ·Angela Schulz,Nicola Specchio,Paul Gissen,Emily de los Reyes,Heather Cahan,Peter Slasor,David Jacoby,Temitayo Ajayi	2019	6
8	Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 study Clinical Immunology ·Anu Cherukuri,Heather Cahan,Nong Pi-zhong,哲村田,Peter Slasor,千恵子塩谷,Joshua Henshaw,Temitayo Ajayi,صادق گلستانی,Charles O’Neill,Becky Schweighardt	2018	25
9	Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study The Lancet Child & Adolescent Health ·Miriam Nickel,Alessandro Simonati,David Jacoby,Susanne Lezius,Jacopo Franzoni,فاطمه نیلی احمد ابادی,Odelya E. Pagovich,Barry E. Kosofsky,Kaleb Yohay,Matthew Downs,Peter Slasor,Temitayo Ajayi,Ronald G. Crystal,Alfried Kohlschütter,Dolan Sondhi,Angela Schulz	2018	89
10	Intracerebroventricular cerliponase alfa for children with CLN2 disease: Interim results from an ongoing phase 2 extension study European Journal of Paediatric Neurology ·Angela Schulz,Nicola Specchio,Paul Gissen,Emily de los Reyes,Heather Cahan,Peter Slasor,Temitayo Ajayi,David Jacoby	2017	2
11	Long-term safety and efficacy of intracerebroventricular enzyme replacement therapy with cerliponase alfa in children with CLN2 disease: interim results from an ongoing multicenter, multinational extension study Molecular Genetics and Metabolism ·Angela Schulz,Nicola Specchio,Paul Gissen,Emily de los Reyes,Heather Cahan,Peter Slasor,Temitayo Ajayi,David Jacoby	2017	2
12	Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study Clinical Therapeutics ·Brian Long,Troy Tompkins,Celeste Decker,Lynne Jesaitis,Shahid Niaz Khan,Peter Slasor,Paul Harmatz,Charles O’Neill,Becky Schweighardt	2016	26
13	Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome Molecular Genetics and Metabolism ·Christian J. Hendriksz,Rossella Parini,Moeenaldeen AlSayed,Julian Raiman,Roberto Giugliani,Rajkinkar Chakraborty,John J. Mitchell,Barbara K. Burton,Norberto Guelbert,Fiona Stewart,Derralynn Hughes,Kenneth I. Berger,Peter Slasor,Robert Matousek,Elaina Jurecki,Adam J. Shaywitz,Paul Harmatz	2016	50
14	Longitudinal analysis of endurance and respiratory function from a natural history study of Morquio A syndrome Molecular Genetics and Metabolism ·Paul Harmatz,Eugen Mengel,Roberto Giugliani,Vassili Valayannopoulos,Shuan-Pei Lin,Rossella Parini,Nathalie Guffon,Barbara K. Burton,Christian J. Hendriksz,John J. Mitchell,Ana María Martins,Simon Jones,Norberto Guelbert,Ashok Vellodi,Frits A. Wijburg,Kehu Yang,Peter Slasor,Celeste Decker	2014	31
15	The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects Molecular Genetics and Metabolism ·Paul Harmatz,Eugen Mengel,Roberto Giugliani,Vassili Valayannopoulos,Shuan-Pei Lin,Rossella Parini,Nathalie Guffon,Barbara K. Burton,Christian J. Hendriksz,John J. Mitchell,Ana María Martins,Simon Jones,Norberto Guelbert,Ashok Vellodi,Carla E. M. Hollak,Peter Slasor,Celeste Decker	2013	110
16	Does the Sedative Agent Facilitate Emergency Rapid Sequence Intubation? Academic Emergency Medicine ·Marco L.A. Sivilotti,Michael R. Filbin,Heather Murray,Peter Slasor,Ron M. Walls,(unknown)	2003	50
17	Joint models for efficient estimation in proportional hazards regression models Statistics in Medicine ·Peter Slasor,Nan M. Laird	2003	8
18	Analysis of myopathy in a placebo-controlled zidovudine trial Muscle & Nerve ·David M. Simpson,Peter Slasor,Urania Dafni,Joseph Berger,Margaret A. Fischl,Colin D. Hall	1997	20
19	Stable neurological function in subjects treated with 23-dideoxyinosine Journal of NeuroVirology ·T Greulich,Urania Dafni,Peter Slasor,Colin D. Hall,George Dascalopoulos,Karl Kieburtz,Thomas J. Tucker,Monika Althoff	1997	7
20	Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal databreakdown → Statistics in Medicine ·Avital Cnaan,Nan M. Laird,Peter Slasor	1997	1017

About Peter Slasor

Peter Slasor is a scholar working on Rheumatology, Physiology, Physiology, Metals and Alloys and Statistics and Probability, having authored 29 papers that have together received 3.1k indexed citations. Recurring topics across this work include Lysosomal Storage Disorders Research (20 papers), Glycogen Storage Diseases and Myoclonus (14 papers), Trypanosoma species research and implications (8 papers), Biochemical and Molecular Research (4 papers), Cellular transport and secretion (4 papers), Statistical Methods and Bayesian Inference (2 papers), Statistical Methods and Inference (2 papers) and Calcium signaling and nucleotide metabolism (2 papers). The work is most often cited by research in Pathology and Forensic Medicine (1.0k citations), Rheumatology (654 citations), Neurology (645 citations), Physiology (806 citations) and Psychiatry and Mental health (263 citations). Peter Slasor has collaborated with scholars based in United States, Germany and Italy. Frequent co-authors include Nan M. Laird, Avital Cnaan, Lawrence Jacobs, R. Phillip Kinkel, T. J. Murray, Alfred Sandrock, Nancy A. Simonian, Carol M. Brownscheidle, Jack H. Simon and Roy W. Beck. Their work appears in journals such as Molecular Genetics and Metabolism, New England Journal of Medicine, Statistics in Medicine, Journal of Inherited Metabolic Disease and Clinical and Translational Science.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact